Free Trial
NASDAQ:GPCR

Structure Therapeutics Q2 2023 Earnings Report

Structure Therapeutics logo
$18.96 +0.17 (+0.88%)
As of 02:47 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Structure Therapeutics EPS Results

Actual EPS
-$0.20
Consensus EPS
-$0.19
Beat/Miss
Missed by -$0.01
One Year Ago EPS
N/A

Structure Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Structure Therapeutics Announcement Details

Quarter
Q2 2023
Time
N/A
Conference Call Date
Thursday, August 10, 2023
Conference Call Time
7:00AM ET

Structure Therapeutics Earnings Headlines

Structure Therapeutics: Key Milestones Dead Ahead
Amazon’s big Bitcoin embarrassment
Bitcoin just passed Amazon in total market cap — but most investors are missing the bigger opportunity. While the crowd buys Bitcoin outright, trader Larry Benedict is using a method called “Bitcoin Skimming” to target 6x, 9x, even 22x bigger profits. He reveals how it works in a free video.tc pixel
Equities Analysts Set Expectations for GPCR FY2025 Earnings
See More Structure Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Structure Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Structure Therapeutics and other key companies, straight to your email.

About Structure Therapeutics

Structure Therapeutics (NASDAQ:GPCR) Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity. It is also developing oral small molecule therapeutics targeting other GPCRs for the treatment of pulmonary and cardiovascular diseases, including ANPA-0073, a biased agonist for apelin receptor, a GPCR that has been implicated in idiopathic pulmonary fibrosis (IPF); and LTSE-2578, an investigational oral small molecule lysophosphatidic acid 1 receptor antagonist for the treatment of IPF and PPF. The company was formerly known as ShouTi Inc. Structure Therapeutics Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.

View Structure Therapeutics Profile

More Earnings Resources from MarketBeat